NeoGenomics, Inc.

NEO ·Healthcare, Diagnostics & Research, United States

Net Cash Flow Breakdown

FY2025 FY2024 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2011

Total Cash from Operations: $2.4M

Line Item	Value	% of Total
Capital Expenditures	$897.0K	36.9%
Net Cash Flow	$1.5M	63.1%